Program
HRS-9563
A development code. Also written as “HRS-9563 Injection”.
Its studies are mostly in Hypertension, led by Jiangsu HengRui Medicine.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 11 open or running | phase 2since Dec 9, 2025 | Dec 9, 2025 | Dec 2026phase 2 · NCT07297797 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Dec 9, 2025First study: phase 2 study in Mild to Moderate HypertensionFirst studyNCT07297797 · 238 enrolled · China
Ahead
- Dec 2026Primary completion: phase 2 study in Mild to Moderate HypertensionNCT07297797
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07297797Mild to Moderate Hypertension · China | 2 | Active, not recruiting | Dec 2026 | 238 |
How it is read
Names in the registry
- “HRS-9563 Injection”, 1 entry
Codes read as this program: HRS9563.
Conditions, from the studies’ own filings
- Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.